Latest News on PCVX

Financial News Based On Company


Advertisement
Advertisement

Vaxcyte at jefferies global healthcare conference: adult vaccine path sharpens

https://www.investing.com/news/transcripts/vaxcyte-at-jefferies-global-healthcare-conference-adult-vaccine-path-sharpens-93CH-5035224
Vaxcyte provided updates on its pneumococcal vaccine franchise at the Jefferies Global Healthcare Conference, highlighting positive Phase III adult study data for VAX-31 which met all endpoints and demonstrated non-inferiority to existing vaccines while offering broader coverage. The company aims for a biologics license application filing in the first half of 2028 and anticipates Phase II infant program data in the first half of 2027. Vaxcyte sees a substantial commercial opportunity in the adult market, which is expected to grow significantly, driven by broader serotype coverage.

A passive stake tops 5% at Vaxcyte (PCVX), with three Wellington entities reporting ownership.

https://www.stocktitan.net/sec-filings/PCVX/schedule-13g-vaxcyte-inc-passive-investment-disclosure-5-701582624c69.html
Three Wellington entities—Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP—have reported a passive stake of 5.2% in Vaxcyte, Inc. (PCVX). As of September 30, 2026, each entity beneficially owned 7,733,961 common shares, with shared voting power over 6,603,132 shares and shared dispositive power over all 7,733,961 shares. This disclosure, made via a Schedule 13G filing, indicates a significant, non-controlling investment in the biotechnology company.

Vaxcyte’s VAX-31 Pneumococcal Vaccine Meets All Phase 3 Primary Goals

https://www.drugtopics.com/view/vaxcyte-s-vax-31-pneumococcal-vaccine-meets-all-phase-3-primary-goals
Vaxcyte's VAX-31, a 31-valent pneumococcal conjugate vaccine, successfully met all primary endpoints in its pivotal phase 3 OPUS-1 trial, demonstrating noninferior immune responses compared to PCV20 and PCV21 for shared serotypes, and superior responses for unique serotypes. The vaccine was well-tolerated with a safety profile similar to existing PCVs, making it a strong candidate for future FDA Biologics License Application. This broader-spectrum vaccine aims to cover a wider range of pneumococcal disease strains, offering significant potential to reduce the burden of adult pneumonia and invasive pneumococcal disease.

Vaxcyte Stock After Wider Q3 Losses Has The Bull Case Changed?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-stock-after-wider-q3-losses-has-the-bull-case-change
Vaxcyte (NasdaqGS:PCVX) reported wider Q3 2026 losses of US$297.06 million, with a basic loss per share of US$1.99, reflecting heavy R&D and manufacturing spending in its pre-revenue phase. The investment narrative remains focused on clinical and regulatory progress for late-stage vaccine programs like VAX 31 and VAX A1, rather than earnings. The primary risk is increased cash usage potentially accelerating funding needs, although the company currently holds about US$3.0 billion in cash and investments, projected to last until at least the end of 2028.

Form 144 Vaxcyte For: 12 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-vaxcyte-for-12-november-93CH-4953418
Investing.com reports on a Form 144 filing for Vaxcyte (PCVX) dated November 12. The article provides the title of the filing and mentions Vaxcyte's stock symbol and current performance.
Advertisement

A 17,000-share sale is planned by Vaxcyte (PCVX) officer Harpreet S. Dhaliwal.

https://www.stocktitan.net/sec-filings/PCVX/144-vaxcyte-inc-sec-filing-449e0f4621eb.html
Vaxcyte officer Harpreet S. Dhaliwal plans to sell 17,000 common shares of Vaxcyte (PCVX), valued at approximately $1.15 million, with an approximate sale date of November 11, 2026. This planned sale follows a previous sale of 17,000 common shares on August 5, 2026, for over $935,000, and an acquisition of 17,000 shares through stock options on November 11, 2026. The transaction is reported via a Form 144 SEC filing.

PCVX: VAX-31 data support a broad-coverage PCV, with adult BLA targeted for H1 2028

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4558674:0-pcvx-vax-31-data-support-a-broad-coverage-pcv-with-adult-bla-targeted-for-h1-2028/
Vaxcyte, Inc. (PCVX) announced positive adult phase III results for its VAX-31 vaccine, meeting primary endpoints and demonstrating significant incremental coverage over PCV20. The company anticipates releasing OPUS-2/3 data in H1 2027, infant data by end-H1 2027, and plans to submit the Biologics License Application (BLA) for adults in H1 2028. This information is based on an AI-generated summary of the company's 3rd Annual Guggenheim Healthcare Innovation Conference Audio Transcript from November 10, 2026.

Weekly Recap: VAX-31 meets OPUS-1 goals and R&D costs rise 54%

https://www.tradingview.com/news/tradingview:dee04470a4c8c:0-weekly-recap-vax-31-meets-opus-1-goals-and-r-d-costs-rise-54/
Vaxcyte, Inc. (NASDAQ:PCVX) announced that its VAX-31 vaccine met all primary immunogenicity goals and was well tolerated in the Phase 3 OPUS-1 adult trial. While OPUS-2 and OPUS-3 results are anticipated in the first half of 2027, the company reported a 54% year-over-year increase in R&D costs for the first nine months of 2026, leading to increased third-quarter losses.

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: T. Rowe Price Investment Management, Inc.

https://www.streetinsider.com/SEC+Filings/Form+SCHEDULE+13GA+Vaxcyte%2C+Inc.+Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./27305765.html
T. Rowe Price Investment Management, Inc. filed an Amendment No. 2 to Schedule 13G regarding its ownership in Vaxcyte Inc. As of September 30, 2026, T. Rowe Price Investment Management, Inc. beneficially owned 14,312,368 shares, representing 9.6% of the common stock. The filing indicates sole voting power over 13,699,251 shares and sole dispositive power over all 14,312,368 shares.

T. Rowe Price updates its reported Vaxcyte (PCVX) stake; one fund holds 5.2%.

https://www.stocktitan.net/sec-filings/PCVX/schedule-13g-a-vaxcyte-inc-amended-passive-investment-disclosure-98b7965fe25a.html
T. Rowe Price Investment Management, Inc. has filed an amended ownership report for Vaxcyte, Inc. (PCVX), disclosing beneficial ownership of 18,136,166 common shares, which represents 11.6% of the class. The filing specifies that T. Rowe Price Capital Appreciation Fund holds 7,430,887 shares, accounting for 5.2% of the class. The investment manager clarified that clients or their custodians are entitled to dividends and sale proceeds, with clients retaining ultimate control over their receipt.
Advertisement

BTIG Sticks to Their Buy Rating for Vaxcyte (PCVX)

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8696386/btig-sticks-to-their-buy-rating-for-vaxcyte-pcvx/
BTIG analyst Thomas Shrader maintained a Buy rating on Vaxcyte (PCVX) with an $89.00 price target. The company's shares closed at $65.68 yesterday, and the overall analyst consensus for Vaxcyte is a Strong Buy with a $122.00 average price target. Vaxcyte recently reported a quarterly GAAP net loss of $284.3 million for the quarter ending June 30.

Vaxcyte Stock Gets A Lift From Strong Vaccine Trial Results

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-stock-gets-a-lift-from-strong-vaccine-trial-results
Vaxcyte (NasdaqGS:PCVX) announced positive topline OPUS-1 Phase 3 data for its VAX-31 pneumococcal vaccine candidate in adults, which met all primary endpoints and showed a safety profile similar to existing vaccines. This positive clinical readout provides a significant boost to the company's investment narrative, balancing its substantial net losses and high R&D spending. The success supports the firm's path towards a Biologics License Application and potential commercialization, projecting a move from zero revenue to US$748.4 million revenue by 2029.

Vaxcyte, Inc. (PCVX) Tops Q3 EPS by 14c

https://www.streetinsider.com/Earnings/Vaxcyte%2C+Inc.+%28PCVX%29+Tops+Q3+EPS+by+14c/27293917.html
Vaxcyte, Inc. (NASDAQ: PCVX) reported a Q3 EPS of ($1.99), surpassing the analyst estimate of ($2.13) by $0.14. This indicates a stronger-than-expected financial performance for the quarter.

Form 4 Vaxcyte Inc: Elvia Cowan (SVP, Finance & CAO) For: 2 November

https://au.investing.com/news/stock-market-news/form-4-vaxcyteinc-elvia-cowan-svp-finance--cao-for-2-november-93CH-4745711
This article reports on a Form 4 filing for Vaxcyte Inc, indicating that Elvia Cowan, SVP of Finance & CAO, made a filing on November 2nd. The report is from Investing.com and provides details relevant to stock market performance and insider trading. The content includes a brief mention of Vaxcyte Inc (PCVX) and its stock performance.

Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 2,250 Shares of Stock

https://www.marketbeat.com/instant-alerts/insider-vaxcyte-nasdaq-pcvx-evp-jim-wassil-sells-2250-shares-of-stock-2026-11-04/
Vaxcyte EVP Jim Wassil recently sold 2,250 shares of Vaxcyte (NASDAQ:PCVX) stock for $137,025 under a pre-arranged trading plan, reducing his position by 1.52%. Following the sale, Wassil still holds 145,435 shares valued at over $8.8 million. The company reported adjusted earnings per share of -$1.99, surpassing analyst expectations, and has an average "Moderate Buy" rating with a target price of $110.50.
Advertisement

Form 8K Vaxcyte Inc For: 4 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-vaxcyteinc-for-4-november-93CH-4958368
This article reports on Vaxcyte Inc.'s Form 8K filing for November 4th, 2026. The news, published by Investing.com, notes the company's stock symbol PCVX with a 7.96% increase.

Nine-month operating cash use tops $737M as Vaxcyte (PCVX) posts a wider Q3 loss.

https://www.stocktitan.net/sec-filings/PCVX/10-q-vaxcyte-inc-quarterly-earnings-report-51ad857b9e3a.html
Vaxcyte (PCVX) reported a wider net loss of $297.062 million in Q3 2026, compared to $212.830 million in the same period last year, with research and development expenses increasing significantly. For the first nine months of 2026, net cash used in operating activities surged to $737.177 million from $430.745 million in 2025. Despite the losses, Vaxcyte announced positive topline results from its pivotal Phase 3 OPUS-1 trial for VAX-31 and successfully completed public offerings in October 2026, generating approximately $1.1 billion in net proceeds.

Vaxcyte’s vaccine candidate met every main goal in a trial of 4,047 adults. More trial results are expected in 2027.

https://www.stocktitan.net/news/PCVX/vaxcyte-reports-third-quarter-2026-financial-results-and-provides-cbqda9nvur0i.html
Vaxcyte announced positive topline results from its pivotal Phase 3 OPUS-1 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, which met all primary endpoints in 4,047 adults. The company also reported a widened third-quarter net loss of $297.1 million but strengthened its cash position by raising approximately $1.1 billion net from October equity and convertible note offerings. Vaxcyte expects further trial results for OPUS-2 and OPUS-3 in the first half of 2027 and plans to submit an adult vaccine application in the first half of 2028.

Form 4 Vaxcyte Inc: Jim Wassil (EVP, Chief Scientific Ofc, COO) For: 2 November

https://ca.investing.com/news/stock-market-news/form-4-vaxcyteinc-jim-wassil-evp-chief-scientific-ofc-coo-for-2-november-93CH-4932111
This article reports on a Form 4 filing for Vaxcyte Inc, specifically detailing an insider transaction involving Jim Wassil, the company's EVP, Chief Scientific Officer, and COO, for November 2nd. The filing, published on November 4, 2026, indicates a corporate insider's activity, which is often monitored by investors for insights into a company's financial health and future prospects.

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.globenewswire.com/news-release/2026/11/04/3395828/0/en/vaxcyte-reports-third-quarter-2026-financial-results-and-provides-business-update.html
Vaxcyte, Inc. announced its Q3 2026 financial results and business updates, highlighted by positive topline data from the OPUS-1 pivotal Phase 3 trial for its VAX-31 adult pneumococcal conjugate vaccine candidate. The company also strengthened its balance sheet with $1.1 billion in net proceeds from recent equity and convertible senior notes offerings, bringing its pro forma cash to approximately $3.4 billion, and expects further clinical trial results and BLA submission in the coming years.
Advertisement

The Technical Signals Behind (PCVX) That Institutions Follow

https://news.stocktradersdaily.com/news_release/78/The_Technical_Signals_Behind_PCVX_That_Institutions_Follow_110226114201_1793680921.html
This article analyzes Vaxcyte Inc. (NASDAQ: PCVX) using AI models to identify technical signals and institutional trading strategies. Key findings include positive near-term sentiment within a long-term strength context, a mid-channel oscillation, and a significant risk-reward short setup. The report details specific position trading, momentum breakout, and risk hedging strategies based on multi-timeframe signal analysis.

A 3,000-share sale is planned by Vaxcyte (PCVX) officer Elvia Cowan.

https://www.stocktitan.net/sec-filings/PCVX/144-vaxcyte-inc-sec-filing-ffb26038a02e.html
Vaxcyte, Inc. officer Elvia Cowan plans to sell 3,000 shares of common stock, valued at $185,640, around November 2, 2026, through UBS Financial Services, Inc. This follows a previous sale of 19,000 shares on October 5, 2026, totaling $1,648,060. The transaction is documented in a Form 144 SEC filing, indicating the shares were acquired via the exercise of stock options.

InvestingPro predicted Vaxcyte’s 44% decline two years ago By Investing.com

https://www.investing.com/news/investment-ideas/investingpro-predicted-vaxcytes-44-decline-two-years-ago-93CH-4990738
InvestingPro's Fair Value analysis accurately predicted a 44% decline in Vaxcyte (NASDAQ:PCVX) shares two years ago, flagging the stock as significantly overvalued when it traded at $111.58 in September 2024. Despite strong momentum, the company's deeply unprofitable fundamentals supported the model's intrinsic value estimate of $62.99, demonstrating the utility of valuation methodologies in identifying market discrepancies and informing investment decisions.

Vaxcyte, Inc. Estimates – NASDAQ:PCVX

https://www.tradingview.com/symbols/NASDAQ-PCVX/financials-estimates/
This article from TradingView provides an overview of Vaxcyte, Inc. (NASDAQ: PCVX) financial data and analyst estimates. It highlights sections for income statements, balance sheets, cash flow, and valuation metrics, allowing users to compare actual results with average, high, and low estimates. The platform explicitly states this is not investment advice and encourages users to conduct their own research.

Cantor Fitzgerald sets USD 120 target for Vaxcyte stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cantor-fitzgerald-sets-usd-120-target-for-vaxcyte-stock/70375975
Cantor Fitzgerald has set a USD 120 price target for Vaxcyte stock and maintained an "Overweight" rating, citing the positive OPUS-1 adult Phase 3 trial results for VAX-31. Despite a significant net loss of USD 284.30 million in Q2 2026 due to increased R&D, the company holds USD 2.51 billion in cash, providing financial runway for its clinical programs. The future valuation will depend on clinical execution, cash utilization, and the timing of VAX-31 evidence, with further trial results expected in H1 2027 and a biologics license application planned for H1 2028.
Advertisement

Enterprise value to revenue forward of Vaxcyte, Inc. – MUN:5VA

https://www.tradingview.com/symbols/MUN-5VA/financials-statistics-and-ratios/enterprise-value-sales-fwd/
This article focuses on the "Enterprise value to revenue forward" metric for Vaxcyte, Inc. (MUN:5VA), a biotechnology company listed on the Munich Stock Exchange. It appears to be a financial data point provided by TradingView, with data sourced from ICE Data Services and FactSet. The article provides a high-level overview of the company's financial information within the TradingView platform.

Cantor Fitzgerald sets USD 120.00 target for Vaxcyte stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cantor-fitzgerald-sets-usd-120-00-target-for-vaxcyte-stock/70348860
Cantor Fitzgerald has set a USD 120.00 price target for Vaxcyte (PCVX) stock, maintaining an Overweight rating. This target is 88.62 percent above the stock's October 16, 2026 closing price of USD 63.62. The firm's valuation follows Vaxcyte's second-quarter earnings report, which showed a loss of USD 1.97 per share, beating the consensus estimate.

Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program Advances

https://www.rttnews.com/3699692/show-me-the-money-vaxcyte-delivers-100-gains-as-pneumococcal-vaccine-program-advances.aspx
Vaxcyte Inc. (PCVX) has experienced a significant breakout year in 2026, driven by positive pipeline developments for its pneumococcal vaccine programs, including VAX-31 and VAX-A1. The stock, which was highlighted to readers in October 2025 at $42.30, reached a 52-week high of $90.75, representing a 115% gain, before settling around $65. Key catalysts include positive Phase 3 trial results for VAX-31 and upcoming data releases in 2027 for its various vaccine candidates.

Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program Advances

https://www.rttnews.com/amp/3699692/show-me-the-money-vaxcyte-delivers-100-gains-as-pneumococcal-vaccine-program-advances.aspx
Vaxcyte Inc. (PCVX) has achieved significant stock gains, exceeding 100% since October 2025, driven by advancements in its pneumococcal vaccine program. The company's lead candidate, VAX-31, a 31-valent pneumococcal conjugate vaccine, recently reported positive topline results from its OPUS-1 pivotal adult Phase 3 trial. Vaxcyte continues to develop other vaccine candidates, including VAX-A1 for Group A Streptococcus disease, with several key data readouts anticipated through 2027.

Vaxcyte (PCVX), What Is Behind The Fresh Attention?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-what-is-behind-the-fresh-attention
Vaxcyte (PCVX) has gained significant attention after its VAX-31 pneumococcal vaccine candidate successfully met all co-primary immunogenicity endpoints in the Phase 3 OPUS-1 trial, with a safety profile comparable to existing vaccines. The company's stock has seen substantial gains, trading at US$67.55 after a 13.45% 1-month return and a 45.39% year-to-date increase. Despite recent increases, Vaxcyte is still considered 41% undervalued by some narratives, with a fair value estimated around $114.78, though this depends on successful approvals and uptake while managing spending effectively.
Advertisement

Vaxcyte Stock In Focus After Phase 3 Vaccine Trial Success

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-stock-in-focus-after-phase-3-vaccine-trial-success
Vaxcyte (NasdaqGS:PCVX) announced positive Phase 3 trial results for its 31-valent pneumococcal vaccine, VAX-31, meeting all immunogenicity endpoints with a safety profile comparable to existing vaccines. This clinical success is bolstered by approximately $1.0 billion in new capital from equity and convertible note offerings, strengthening the company's financial position for manufacturing and commercialization efforts. The focus now shifts to regulatory assessment and how this milestone will impact Vaxcyte's investment narrative as it moves closer to potential product launch.

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-vaxcyte-125502070.html
Wall Street analysts project a potential 75.6% upside for Vaxcyte (PCVX), with a mean price target of $117.3. While consensus price targets can be misleading due to analyst optimism, a strong agreement in earnings estimate revisions and a Zacks Rank #2 (Buy) suggest a legitimate potential for near-term stock appreciation for PCVX. Investors are advised to use price targets as a starting point for research rather than the sole basis for investment decisions.

How Vaxcyte Inc. (PCVX) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/8/How_Vaxcyte_Inc._PCVX_Affects_Rotational_Strategy_Timing_101326023202_1791916322.html
This article analyzes Vaxcyte Inc. (PCVX) focusing on its impact on rotational strategy timing. It highlights weak near-term sentiment that could precede shifts in mid and long-term outlook, noting an exceptional risk-reward short setup. The analysis provides institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.

Cantor Fitzgerald sets Vaxcyte stock price target at $120 By Investing.com

https://ca.investing.com/news/stock-market-news/cantor-fitzgerald-sets-vaxcyte-stock-price-target-at-120-93CH-4876005
Cantor Fitzgerald has initiated a $120 price target for Vaxcyte (NASDAQ:PCVX) with an Overweight rating, aligning with Wall Street's "Strong Buy" consensus. Despite near-term market pressures and expected data eight months away, the firm updated its model following positive OPUS-1 trial results and subsequent financing. Vaxcyte shares have seen a 63% return over the past year, though InvestingPro indicates it may be trading above its Fair Value.

Vaxcyte EVP, COO Jim Wassil sells $1.56m in shares

https://www.investing.com/news/insider-trading-news/vaxcyte-evp-coo-jim-wassil-sells-156m-in-shares-93CH-4942432
Vaxcyte's EVP, COO Jim Wassil sold 18,000 shares of company stock for $1.56 million on October 5, 2026, though he also acquired the same number of shares through stock options exercise. Following these transactions, Wassil directly holds 145,435 shares. The stock has seen a 63% return over the past year, but InvestingPro analysis suggests it is currently overvalued.
Advertisement

Vaxcyte Bolsters Capital Structure with New Offerings

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/5797021/vaxcyte-bolsters-capital-structure-with-new-offerings/
Vaxcyte (PCVX) has significantly strengthened its financial position by closing concurrent equity and convertible debt offerings, raising approximately $544.3 million from equity and $558.7 million from debt. These transactions, which included issuing $575 million in convertible senior notes and selling common stock and pre-funded warrants, provide the biotechnology company with enhanced financial flexibility for future strategic and operational initiatives. Despite a "Neutral" rating from TipRanks' AI Analyst due to weak financial performance, the company's technicals are supportive, and recent positive corporate events offer a meaningful offset.

Vaxcyte, Inc. Bonds — Corporate Bond Rates

https://www.tradingview.com/symbols/NASDAQ-PCVX/bonds/
This article provides a list of Vaxcyte, Inc. corporate bonds, sorted by yield to worst, noting their increased stability during market volatility. It presents details like symbol, price, coupon, maturity date, outstanding amount, and face value for a specific bond (PCVX6538260). The information aims to help investors find reliable investment opportunities within Vaxcyte's debt securities.

Press Release: Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Convertible Senior Notes

https://www.moomoo.com/news/post/1000857019/press-release-vaxcyte-announces-closing-of-1-15-billion-public
Vaxcyte announced the closing of its public offerings, raising approximately $1.15 billion. This includes offerings of common stock, pre-funded warrants, and convertible senior notes. The underwriters fully exercised their options to purchase additional shares and convertible senior notes.

Vaxcyte (PCVX) Stock Soars As VAX-31 Data Smash Expectations

https://stockstotrade.com/news/vaxcyte-inc-pcvx-news-2026_10_09/
Vaxcyte (PCVX) stock surged significantly after its VAX-31 pneumococcal conjugate vaccine met all primary endpoints in the Phase 3 OPUS-1 trial, outperforming competitors. This positive data has led multiple analysts to reiterate Buy ratings and raise price targets, with some seeing potential for VAX-31 to capture a substantial share of the adult PCV market. While the company still faces future dilution and execution risks as a pre-revenue biotech, the successful trial marks a major de-risking event.

Latham Advises on Vaxcyte Concurrent Public Offerings of Common Stock Pre Funded Warrants

https://www.lw.com/en/news/2026/10/latham-advises-on-vaxcyte-concurrent-public-offerings-of-common-stock-pre-funded-warrants
Latham & Watkins LLP advised the underwriters in Vaxcyte, Inc.'s concurrent public offerings. These offerings included 7,412,500 shares of common stock, pre-funded warrants for 400,000 shares, and US$500 million in convertible senior notes. The offerings involved common stock sold at US$64 per share and pre-funded warrants at US$63.999 per warrant, with Latham's corporate team leading the advisory efforts for the underwriters.
Advertisement

Vaxcyte prices US$1B in stock, warrants and convertible notes

https://mugglehead.com/vaxcyte-us1b-stock-convertible-notes-vax31/
Vaxcyte, Inc. has priced concurrent offerings of stock, warrants, and convertible notes totaling approximately US$1 billion to fund pneumococcal vaccine trials, manufacturing, and U.S. launch preparations for its lead adult candidate, VAX-31. The financing is expected to close on October 9, with proceeds split evenly between equity and notes. The company anticipates results for its OPUS-2 and OPUS-3 adult trials in the first half of 2027, followed by a potential U.S. biologics license application in the first half of 2028.

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

https://www.globenewswire.com/news-release/2026/10/07/3376168/0/en/vaxcyte-announces-pricing-of-concurrent-public-offerings-of-common-stock-pre-funded-warrants-and-convertible-senior-notes.html
Vaxcyte, Inc. announced the pricing of concurrent public offerings, totaling approximately $1 billion in gross proceeds, comprising common stock, pre-funded warrants, and convertible senior notes. The company plans to use these funds to advance its VAX-31 adult and pediatric vaccine programs, scale up manufacturing, prepare for commercial launch, and support other R&D initiatives. The offerings are expected to close on October 9, 2026, with major financial institutions acting as joint book-running managers.

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

https://investingnews.com/vaxcyte-announces-pricing-of-concurrent-public-offerings-of-common-stock-pre-funded-warrants-and-convertible-senior-notes/
Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of concurrent underwritten public offerings including 7,412,500 shares of common stock at $64.00 per share, pre-funded warrants, and $500 million in 1.50% convertible senior notes due 2032. The aggregate gross proceeds from these offerings are expected to reach approximately $1 billion, which Vaxcyte plans to use for the clinical development of its VAX-31 adult and pediatric vaccine programs, manufacturing scale-up, and further research and development of its pipeline. The offerings are expected to close on October 9, 2026, with several major financial institutions acting as joint book-running managers.

As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)

https://www.tikr.com/blog/as-expected-vaxcyte-announces-1-billion-stock-and-convertible-raise-a-day-after-its-phase-3-win-and-sinks-10
Vaxcyte (PCVX) shares dropped 10% after the company announced a $1 billion capital raise, split between stock and convertible notes, shortly after its VAX-31 vaccine achieved a Phase 3 trial win. The raise, anticipated by analysts, is crucial for funding VAX-31's ongoing trials, scaling manufacturing, and building inventory, as the company is still years away from revenue generation and has seen a significant increase in operational cash burn. Despite the stock drop, which reflects expected dilution, analysts like BofA maintained a "Buy" rating, raising their price target.

Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027

https://seekingalpha.com/article/4952335-vaxcyte-strong-buy-vax-31-trial-win-ipd-vax-31-and-additional-readouts-1st-half-2027
Vaxcyte has received a 'Strong Buy' rating following the robust phase 3 OPUS-1 results for its VAX-31 vaccine, which demonstrated non-inferiority to existing vaccines. The company is poised for significant upside with multiple catalysts in the first half of 2027, including further phase 3 data for VAX-31 in adults and phase 2 infant data. VAX-31 aims to provide broader pneumococcal strain coverage, and Vaxcyte's strong cash position supports its pipeline, including an early-stage vaccine for Group A Streptococcus.
Advertisement

Vaccine developer looks to raise $1 billion after successful clinical trial

https://www.bizjournals.com/sanfrancisco/news/2026/10/06/vaccines-pneumococcal-vaxcyte-merck-pfizer.html
Vaxcyte, a vaccine developer, plans to raise $1 billion after a successful clinical trial for its pneumococcal disease vaccine. The company aims to seek regulatory approval for the vaccine in 2028. This move follows the positive outcome of their clinical trial announced earlier this week.

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

https://finance.yahoo.com/healthcare/articles/vaxcyte-announces-commencement-proposed-public-202800170.html
Vaxcyte, Inc. announced the commencement of underwritten public offerings for $500 million of common stock and pre-funded warrants, and $500 million in convertible senior notes due 2032. The company plans to use the net proceeds to fund the clinical development of its VAX-31 adult and pediatric programs, support manufacturing scale-up, prepare for the U.S. launch of VAX-31 in adults, and advance other early-stage vaccine candidates. The offerings are subject to market conditions and are not contingent on each other.

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

https://investingnews.com/vaxcyte-announces-commencement-of-proposed-public-offerings-of-common-stock-pre-funded-warrants-and-convertible-senior-notes/
Vaxcyte, Inc. has announced the commencement of two separate underwritten public offerings: one for $500 million of common stock and pre-funded warrants, and another for $500 million aggregate principal amount of convertible senior notes due 2032. The company intends to use the net proceeds from both offerings primarily to fund the clinical development of its VAX-31 adult and pediatric vaccine programs, support manufacturing scale-up, and invest in commercial preparations for VAX-31's anticipated U.S. launch. The offerings are subject to market conditions and each offering's completion is not contingent on the other.

Vaxcyte stock falls on $1B dual offering launch

https://finance.yahoo.com/markets/stocks/articles/vaxcyte-stock-falls-1b-dual-212645548.html
Vaxcyte Inc. (NASDAQ: PCVX) shares declined by 3.3% in after-hours trading following the announcement of dual public offerings totaling $1 billion. The clinical-stage vaccine company is launching underwritten public offerings of $500 million in common stock and pre-funded warrants, along with $500 million in convertible senior notes due 2032. The proceeds will fund clinical development for its VAX-31 adult and pediatric programs, manufacturing scale-up, and R&D for early-stage vaccine candidates.

Vaxcyte Announces Positive Phase 3 Results for VAX-31

https://www.tipranks.com/news/company-announcements/vaxcyte-announces-positive-phase-3-results-for-vax-31
Vaxcyte announced positive topline data from its pivotal OPUS-1 Phase 3 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine. The trial successfully met all primary immunogenicity and safety endpoints compared to existing vaccines, demonstrating broad serotype coverage and a favorable safety profile. These results support a planned Biologics License Application and suggest VAX-31 could offer enhanced protection against pneumococcal disease in adults.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement